PG
VRTX icon

PEAK6 Group’s Vertex Pharmaceuticals VRTX Stock Holding History

PEAK6 Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$16.4M Buy
96,500
+35,600
+58% +$5.52M 0.07% 271
2018
Q1 		$9.93M Buy
60,900
+60,300
+10,050% +$9.85M 0.04% 454
2017
Q4 		$90K Sell
600
-14,400
-96% -$2.13M ﹤0.01% 3575
2017
Q3 		$2.28M Sell
15,000
-38,000
-72% -$5.72M 0.01% 1276
2017
Q2 		$6.83M Buy
53,000
+52,000
+5,200% +$6.26M 0.04% 549
2017
Q1 		$109K Sell
1,000
-1,200
-55% -$106K ﹤0.01% 3535
2016
Q4 		$162K Sell
2,200
-1,100
-33% -$89.5K ﹤0.01% 3519
2016
Q3 		$288K Sell
3,300
-11,900
-78% -$1.12M ﹤0.01% 2849
2016
Q2 		$1.31M Sell
15,200
-3,500
-19% -$302K 0.01% 1579
2016
Q1 		$1.49M Buy
18,700
+7,300
+64% +$660K 0.01% 1365
2015
Q4 		$1.43M Sell
11,400
-39,900
-78% -$4.82M 0.01% 1614
2015
Q3 		$5.34M Buy
51,300
+18,100
+55% +$2.33M 0.03% 845
2015
Q2 		$4.1M Buy
33,200
+25,200
+315% +$3.18M 0.02% 960
2015
Q1 		$944K Sell
8,000
-179,800
-96% -$21.5M 0.01% 1931
2014
Q4 		$22.3M Sell
187,800
-56,100
-23% -$6.32M 0.17% 107
2014
Q3 		$27.4M Buy
243,900
+175,100
+255% +$16.7M 0.21% 73
2014
Q2 		$6.51M Sell
68,800
-17,900
-21% -$1.26M 0.06% 392
2014
Q1 		$6.13M Buy
86,700
+59,200
+215% +$4.69M 0.05% 505
2013
Q4 		$2.04M Sell
27,500
-130,700
-83% -$9.1M 0.01% 1438
2013
Q3 		$6M Buy
158,200
+85,700
+118% +$6.82M 0.04% 624
2013
Q2 		$5.8K Buy
+72,500
New +$5.34M 0.02% 642

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PEAK6 Group's VRTX Position: Q1 2018 in Review

PEAK6 Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2018, closing a stake of 15,094 shares — an estimated $2.47M sold.

PEAK6 Group first reported a position in VRTX in Q2 2013 and held it in 12 quarters. The position peaked at $3.47M in Q1 2017. 680 funds tracked by Wall St. Rank hold VRTX as of Q1 2018.

  • PEAK6 Group reported no remaining Vertex Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • PEAK6 Group sold 15,094 Vertex Pharmaceuticals shares in Q1 2018, an estimated $2.47M.
  • PEAK6 Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • PEAK6 Group's Vertex Pharmaceuticals position peaked at $3.47M in Q1 2017.
  • 680 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2018.

Based on PEAK6 Group's 13F filing for Q1 2018, filed 15 May 2018.